Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States

Susan Hariri, Lauri E. Markowitz(Centers for Disease Control and Prevention), Matthew F. Daley(Kaiser Permanente), Dennis Tolsma(Kaiser Permanente), Megan S. Schuler(Harvard University), Sophia R. Newcomer(University of Montana), Bradley Crane, Sheila Weinmann(Kaiser Permanente), Allison L. Naleway(Centers for Disease Control and Prevention)
American Journal of Epidemiology
June 14, 2017
10.1093/aje/kwx253
Cited by 34

Related Papers

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Prevalence of HPV Infection Among Females in the United States
|JAMA|2007|1.6k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
|PubMed|2015|1.1k
Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States
|JAMA|2006|1k